Brief: Dice Therapeutics Announces Positive Topline Data From Phase 1 Clinical Trial Of Lead Oral Il-17 Antagonist, Dc-806, For Psoriasis

Dice Therapeutics

11/10/2022 12:31

Oct 11 (Reuters) - Dice Therapeutics Inc  DICE.O :
    * DICE THERAPEUTICS ANNOUNCES POSITIVE TOPLINE DATA FROM
PHASE 1
CLINICAL TRIAL OF LEAD ORAL IL-17 ANTAGONIST, DC-806, FOR
PSORIASIS
    * DC-806 WAS WELL TOLERATED WITH AN EXCELLENT SAFETY PROFILE
ACROSS ALL DOSE GROUPS
    * DC-806 IS EXPECTED TO ADVANCE INTO A PHASE 2B CLINICAL
TRIAL IN
FIRST HALF OF 2023
    * DICE PLANS TO ADVANCE DC-806 INTO A DOSE-RANGING PHASE 2B
CLINICAL TRIAL IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS
    * PLANS TO SUBMIT AN IND APPLICATION WITH U.S. FDA IN FIRST
HALF
OF 2023 AND INITIATE PHASE 2B DEVELOPMENT

Source text for Eikon:  ID:nGNX8cs3dk 
Further company coverage:  DICE.O